One area of focus is its genetic profile. BA.3.2 carries a large number of mutations in the spike protein—the part of the virus involved in entering human cells. This makes it distinct from more recent circulating strains. Because of that difference, early laboratory findings suggest that existing antibodies, whether from prior infection or recent vaccination, may not recognize it as effectively.
In some regions, the variant has grown in proportion among sequenced cases, which may indicate a transmission advantage in populations with existing immunity. However, this remains under observation. Changes in prevalence do not automatically translate into changes in overall impact.
Importantly, current data does not indicate that this variant leads to more severe illness. Reported symptoms are consistent with recent strains—sore throat, fatigue, congestion, and cough. While individual experiences can vary, there is no clear signal at this stage of increased severity.
